Q3 2018 EPS Estimates for Horizon Pharma PLC Boosted by Analyst (HZNP)

Share on StockTwits

Horizon Pharma PLC (NASDAQ:HZNP) – Piper Jaffray Companies upped their Q3 2018 earnings per share (EPS) estimates for shares of Horizon Pharma in a research report issued on Wednesday, August 8th. Piper Jaffray Companies analyst D. Amsellem now anticipates that the biopharmaceutical company will post earnings per share of $0.47 for the quarter, up from their previous forecast of $0.46. Piper Jaffray Companies has a “Buy” rating and a $25.00 price target on the stock. Piper Jaffray Companies also issued estimates for Horizon Pharma’s Q4 2018 earnings at $0.53 EPS, Q1 2019 earnings at $0.29 EPS, Q2 2019 earnings at $0.59 EPS, Q3 2019 earnings at $0.56 EPS, Q4 2019 earnings at $0.67 EPS, FY2019 earnings at $2.11 EPS and FY2020 earnings at $2.59 EPS.

Horizon Pharma (NASDAQ:HZNP) last released its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.17. The company had revenue of $302.84 million for the quarter, compared to analyst estimates of $275.51 million. Horizon Pharma had a negative net margin of 28.02% and a positive return on equity of 19.05%. Horizon Pharma’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.41 EPS.

Several other research firms have also weighed in on HZNP. BidaskClub upgraded shares of Horizon Pharma from a “buy” rating to a “strong-buy” rating in a research note on Friday. Jefferies Financial Group boosted their price objective on shares of Horizon Pharma from $21.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday. Mizuho restated a “buy” rating and set a $18.00 price objective on shares of Horizon Pharma in a research note on Wednesday, August 8th. Cowen restated a “buy” rating and set a $25.00 price objective on shares of Horizon Pharma in a research note on Thursday. Finally, Cantor Fitzgerald set a $21.00 price objective on shares of Horizon Pharma and gave the stock a “buy” rating in a research note on Wednesday, August 8th. Four equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $20.27.

Horizon Pharma stock opened at $20.95 on Monday. The stock has a market cap of $3.48 billion, a PE ratio of 17.75, a PEG ratio of 1.26 and a beta of 1.43. Horizon Pharma has a fifty-two week low of $11.17 and a fifty-two week high of $21.10. The company has a current ratio of 1.70, a quick ratio of 1.50 and a debt-to-equity ratio of 2.19.

Several hedge funds have recently made changes to their positions in the stock. United Services Automobile Association boosted its holdings in shares of Horizon Pharma by 11.0% during the 2nd quarter. United Services Automobile Association now owns 27,036 shares of the biopharmaceutical company’s stock worth $448,000 after buying an additional 2,679 shares during the period. SG Americas Securities LLC boosted its holdings in shares of Horizon Pharma by 25.9% during the 2nd quarter. SG Americas Securities LLC now owns 16,821 shares of the biopharmaceutical company’s stock worth $279,000 after buying an additional 3,463 shares during the period. Amalgamated Bank boosted its holdings in shares of Horizon Pharma by 17.2% during the 2nd quarter. Amalgamated Bank now owns 25,270 shares of the biopharmaceutical company’s stock worth $418,000 after buying an additional 3,711 shares during the period. Ladenburg Thalmann Financial Services Inc. boosted its holdings in shares of Horizon Pharma by 74.4% during the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 9,091 shares of the biopharmaceutical company’s stock worth $128,000 after buying an additional 3,877 shares during the period. Finally, Rhumbline Advisers boosted its holdings in shares of Horizon Pharma by 2.2% during the 2nd quarter. Rhumbline Advisers now owns 185,346 shares of the biopharmaceutical company’s stock worth $3,069,000 after buying an additional 3,941 shares during the period. 84.72% of the stock is owned by institutional investors and hedge funds.

In related news, EVP Brian K. Beeler sold 17,931 shares of Horizon Pharma stock in a transaction dated Friday, May 25th. The shares were sold at an average price of $16.11, for a total transaction of $288,868.41. Following the completion of the sale, the executive vice president now owns 110,524 shares of the company’s stock, valued at approximately $1,780,541.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Timothy P. Walbert sold 83,353 shares of Horizon Pharma stock in a transaction dated Friday, June 1st. The stock was sold at an average price of $16.17, for a total transaction of $1,347,818.01. The disclosure for this sale can be found here. Insiders have sold a total of 116,717 shares of company stock valued at $1,907,999 in the last ninety days. 3.90% of the stock is currently owned by insiders.

About Horizon Pharma

Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.

Read More: Stock Symbol

Earnings History and Estimates for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply